Ponesimod, a selective sphingosine 1-phosphate (S1P1) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition

• Published in: Xenobiotica Vol. 48; no. 5; pp. 442 - 451
• Main Authors: Dash, Ranjeet Prasad, Rais, Rana, Srinivas, Nuggehally R.
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 04.05.2018
• Subjects: Autoimmune; Autoimmune Diseases - drug therapy; clinical; Dosage Forms; Dose-Response Relationship, Drug; drug interaction pharmacokinetics; Drug Interactions; Humans; ponesimod; Receptors, Lysosphingolipid - metabolism; Thiazoles - chemistry; Thiazoles - pharmacokinetics; Thiazoles - therapeutic use; ponesimod; clinical; Autoimmune; drug interaction pharmacokinetics

1. Ponesimod, a selective sphingosine 1-phosphate (S1P 1 ) receptor modulator, is undergoing clinical development for the treatment of autoimmune diseases (multiple sclerosis/psoriasis). 2. Published literature data describing pharmacokinetic disposition of ponesimod were collected, reviewed and tab...